Saipem and Subsea7 merger faces likely EU antitrust probe as July 22 deadline nears

Saipem S.p.A. (Euronext Milan: SPM) and Subsea7 S.A. (Oslo Børs: SUBC) are approaching a pivotal European regulatory deadline for their proposed merger of equals. The European Commission is expected to open an in-depth antitrust investigation after its preliminary review ends on July 22, 2026, unless the companies offer remedies that resolve competition concerns. Potential measures could include reducing offshore construction capacity or selling vessels, which would cut directly into the operational logic supporting the planned Saipem7 combination. The development matters because the transaction would unite two of the largest fleets and engineering platforms serving subsea oil, gas and offshore energy projects. Investors must now assess whether regulatory concessions can preserve both the second-half 2026 closing target and the merger’s €300 million annual synergy ambition.

Why could the European Commission escalate the Saipem and Subsea7 merger review?

The European Commission’s merger register lists case M.12236, Saipem and Subsea7, as ongoing, while the reported full investigation remains an expected next step rather than a formally announced decision. That distinction is important. A preliminary review asks whether the transaction can be cleared quickly, while an in-depth review would give Brussels more time to test market definitions, customer alternatives, fleet availability and the credibility of any proposed remedies.

The competition question is narrower than whether the offshore services sector has numerous company names. Large subsea developments require engineering depth, project management, fabrication access, specialized installation vessels, suitable mission equipment and available scheduling windows. A contractor that looks credible on a generic market-share table may not be capable of executing a technically demanding deepwater project in the required geography and timeframe.

Saipem and Subsea7 therefore face scrutiny over effective capacity, not merely nominal fleet numbers. If regulators conclude that too few suppliers can bid independently for complex subsea umbilicals, risers and flowlines, the merger could be viewed as removing an important competitive constraint. The companies can argue that their assets and geographic strengths are complementary, but regulators may ask whether customers would lose a bidder precisely when offshore project pipelines are expanding and vessel schedules are tightening.

What makes Saipem7 strategically attractive despite growing regulatory resistance?

The merger agreement uses an EU cross-border structure under which Subsea7 would be absorbed into Saipem, with the surviving company renamed Saipem7. Participating Subsea7 shareholders would receive 6.688 new Saipem shares for each Subsea7 share, producing 50-50 ownership between the two existing shareholder groups if all eligible holders participate. Subsea7 shareholders are also due a €450 million extraordinary dividend immediately before the merger becomes effective. Shareholders of both companies approved the transaction in September 2025, leaving regulatory approvals as the central closing condition.

The strategic appeal rests on scale and asset utilization. The transaction plan envisages more than 60 owned and chartered construction vessels covering heavy lift, J-lay, S-lay, rigid reel lay, flexible pipe installation and offshore wind work. Its 2024 reference case combined €21.2 billion of revenue, €2.4 billion of EBITDA and a broad offshore, onshore and drilling portfolio. The proposed structure would place Offshore Engineering and Construction, including offshore wind, in an operationally autonomous Subsea7 business within Saipem7, while the wider group would retain Onshore Engineering and Construction, Sustainable Infrastructures and Offshore Drilling.

Management identified approximately €300 million of annual cost and capital expenditure synergies by the third year after completion, against about €200 million of one-time implementation costs. Roughly €200 million was expected from operating expenses, €75 million from capital expenditure and €25 million from process efficiencies. Fleet positioning, longer charter periods, procurement terms, tendering discipline and fewer unnecessary intercontinental vessel transits are practical sources of value. They are also the reason the competition review matters so much, because the same coordination that can lower costs may reduce the number of independent fleet owners competing for major projects.

How would vessel divestments or capacity remedies change the economics of Saipem7?

A vessel remedy would not have a uniform financial impact. Selling a relatively interchangeable asset with limited strategic utilization would be manageable, while losing a scarce high-specification installation vessel could weaken bidding capability across an entire category of projects. Value also depends on the mission equipment, crew expertise, regional positioning, maintenance status and contracts attached to an asset. A bare vessel sale may create less competitive capacity than a divestment package containing the people, technology and commercial access needed to operate it independently.

The synergy plan is particularly exposed because fleet optimization is one of its foundations. Saipem7 expects to raise utilization, allocate vessels to regions more efficiently and reduce duplicated commercial effort. A remedy that removes capacity could preserve the legal transaction while eroding the operational flexibility that justified it. If the companies must sell attractive assets at a regulatory timetable rather than a commercial timetable, proceeds may also fail to compensate for lost earnings and reduced strategic optionality.

Regulators must balance remedy simplicity against market effectiveness. A clean asset divestment is easier to monitor than a behavioral promise, but it requires a credible buyer capable of maintaining the asset as a competitive force. Capacity reductions without a viable new owner could shrink supply rather than protect competition. Conversely, a remedy package that establishes or strengthens an independent rival could ease customer concerns but create a better-equipped competitor for Saipem7 immediately after closing.

Why do Australia and Brazil point to sharply different competition outcomes for Saipem7?

Australia moved the merger into a Phase 2 assessment on July 3 after identifying a risk of substantially reduced competition in certain subsea infrastructure services. The focus includes the design, engineering, procurement, fabrication and installation of SURF systems connecting subsea wells and production equipment to surface facilities. Both companies serve Australian offshore projects and operate pipelaying and construction vessels, making the overlap tangible rather than theoretical. Submissions are due on July 21, and the Phase 2 process can run for as long as 90 business days unless the timetable is extended.

Brazil reached the opposite preliminary outcome in June by clearing the merger without restrictions, although opponents have challenged the decision and appeal risk remains. The United Kingdom had already granted Phase 1 clearance in November 2025. These diverging results do not necessarily mean one regulator is permissive and another hostile. They may reflect different customer sets, project pipelines, local content requirements, vessel alternatives and views on whether offshore capacity can move between regions quickly enough to constrain pricing.

That geographic question is central. Construction vessels are mobile, but mobilization is neither instant nor free, and project schedules, weather windows, technical configuration and local operating requirements can limit substitutability. A fleet available in the North Sea may not be a practical answer to an Australian tender with a fixed execution window. Brussels must decide whether competition is global, regional, capability-specific or some combination of all three, and that market definition will shape both the probability and design of remedies.

What do Saipem and Subsea7’s latest results reveal about standalone bargaining power?

Saipem entered the review with first-quarter 2026 revenue of €3.528 billion and adjusted EBITDA of €434 million, up 23.6% from a year earlier. Its adjusted EBITDA margin reached 12.3%, backlog stood at €29.61 billion and pre-IFRS 16 net cash improved to €1.217 billion. Saipem maintained full-year guidance for approximately €15.5 billion of revenue, €1.9 billion of adjusted EBITDA and €600 million of free cash flow after lease repayments. Those figures suggest that Saipem can tolerate a longer review without depending on immediate merger relief.

Subsea7 is similarly well positioned. First-quarter revenue rose 17% to $1.789 billion, adjusted EBITDA increased to $385 million at a 21% margin and net income reached $97 million. Backlog was $13.468 billion, while net cash excluding lease liabilities stood at $535 million. Subsea7 raised its 2026 outlook to revenue of $7.4 billion to $7.8 billion and an adjusted EBITDA margin of about 23%, which increases the value of preserving its strongest assets through any remedy negotiation.

Strong standalone performance cuts both ways. It reduces financing and closing pressure, giving the companies more freedom to defend the original transaction. It also increases the opportunity cost of divesting productive assets or accepting restrictions that constrain bidding. The leadership transition at Subsea7 adds another execution layer: Stuart Fitzgerald became chief executive officer on July 1 and is proposed to lead the autonomous Subsea7 operation within Saipem7, while Saipem chief executive officer Alessandro Puliti remains the intended chief executive of the combined group.

How are Saipem and Subsea7 shares pricing regulatory risk before the July 22 deadline?

Saipem traded at €4.356 in the July 13 session, down 1.29% on the day, approximately 0.9% below its July 6 close and 7.7% lower over one month. The shares remained within a 52-week range of €2.166 to €4.846. On July 10, when the expected EU investigation was reported, Saipem closed unchanged at €4.413, suggesting investors did not immediately treat an extended review as a threat to the company’s standalone value.

Subsea7 traded at NOK329.60 on July 13, down 0.96% in the session, about 1.8% below its July 6 close and 4.5% lower over one month. Its 52-week range was NOK180.10 to NOK358.20. Subsea7 fell 1.71% on July 10, a more visible reaction than Saipem’s, but still modest relative to the share-price gains accumulated during the previous year.

The mixed response implies that markets are pricing delay and remedy risk rather than outright deal failure. Both companies are trading much closer to their 52-week highs than lows, supported by improving margins, large backlogs and stronger offshore spending. Short-term price movement also reflects oil prices, project awards, currency effects and the wider European market, so attributing every fluctuation to antitrust headlines would overstate the signal. The more informative indicator will be relative performance after any formal Phase 2 decision or remedy disclosure, particularly because the fixed share-exchange ratio links the economics received by Subsea7 holders to Saipem’s equity value.

What should customers, competitors and investors watch as the Saipem7 timetable tightens?

The immediate sequence is unusually compressed. Australia’s submission deadline falls on July 21, followed by the reported end of the European Commission’s preliminary review on July 22. A formal in-depth EU investigation would make the second-half closing goal harder to execute, although it would not automatically end it. The companies would then need to decide whether to offer structural remedies early, contest the regulator’s market theory or pursue both tracks while protecting customer and employee confidence.

Customers will watch whether the review changes bidding behavior before the legal merger occurs. Long-dated offshore projects depend on vessel reservations and engineering resources, so uncertainty can influence bid validity, contract conditions and capacity commitments even while Saipem and Subsea7 remain separate competitors. Rivals will assess whether divested assets could provide a rare route to acquiring high-specification capacity without ordering new vessels and waiting through a lengthy construction cycle.

Three outcomes now frame the transaction. A Phase 1 clearance would preserve timing and most of the original synergy case. A conditional approval could keep Saipem7 intact but transfer part of the value to a divestment buyer or customers. A prolonged Phase 2 process would increase integration costs, management distraction and timetable risk while leaving both companies financially capable of operating independently. The decisive question is no longer whether the merger creates scale, but how much of that scale regulators will permit Saipem7 to retain.

What are the key takeaways from the Saipem and Subsea7 antitrust challenge for the offshore industry?

• The expected EU Phase 2 investigation is not yet a formal decision, making July 22 the next critical European milestone.
• Competition concerns center on effective SURF capability and vessel availability, not the headline number of offshore contractors.
• The planned Saipem7 fleet exceeds 60 construction vessels, creating both the merger’s operating advantage and its principal regulatory vulnerability.
• Potential vessel sales could preserve the transaction but weaken fleet utilization, regional flexibility and the €300 million annual synergy target.
• Australia’s Phase 2 review shows that local project conditions can outweigh arguments that offshore construction capacity is globally mobile.
• Brazil’s unconditional clearance and the United Kingdom’s Phase 1 approval demonstrate that regulators can reach different outcomes from the same global transaction.
• Strong first-quarter results and balance sheets give Saipem and Subsea7 room to resist remedies that destroy excessive value.
• The muted share-price reaction suggests investors currently see delay and concessions as more probable than outright deal failure.
• Divestitures could create a strategic acquisition opportunity for rival offshore contractors seeking scarce, high-specification vessel capacity.
• A prolonged review would pressure the second-half 2026 closing target and raise integration risk without undermining either company’s near-term standalone viability.